News

Regeneron Pharmaceuticals, Inc. REGN and partner Sanofi SNY came up with positive detailed results from a phase III trial on Dupixent for the indication of atopic dermatitis in adolescents at in ...
Children with moderate/more extensive atopic dermatitis treated with ruxolitinib cream achieved significant disease control ...
Atopic dermatitis is a chronic skin condition driven by type 2 inflammation, often presenting with more pronounced symptoms and skin lesions in individuals with skin of color. Dupixent was ...
Atopic dermatitis is the most common form of eczema and estimates suggest as many as 300,000 sufferers are in need of new treatment options, the companies said in a joint statement.
(RTTNews) - Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi SA (SNYNF, SNY) announced Saturday positive data from long-term pivotal phase 3 CHRONOS study of DUPIXENT (dupilumab) in moderate-to ...
Sanofi and Regeneron want to stop bullying around atopic dermatitis. So this fall, the drugmaker partners launched the “Agents of Change” AD Challenge and asked people to submit ideas.
Atopic Dermatitis will be one of the key growth franchises for Sanofi and Regeneron. There is a huge unmet meet in this space. Dupixent has been the first branded drug approved for the treatment ...
Chronic spontaneous urticaria places a heavier burden on patients than atopic dermatitis and psoriasis, leading to a worse ...
Regeneron and Sanofi’s pitch for the moderate-to-severe atopic dermatitis market is underpinned by data from a trio of Phase III trials that were unveiled earlier this year. Those studies showed ...
Biotech Regeneron, Sanofi’s hotly tipped atopic dermatitis drug dupilumab accepted for review at EMA By Nick Paul Taylor Dec 8, 2016 5:53am eczema EuroBiotech Report Regeneron Pharmaceuticals Sanofi ...
Regeneron Pharmaceuticals Inc. REGN 1.43% and Sanofi SA SAN -1.34% said their experimental drug for a debilitating skin condition called atopic dermatitis met all of its major treatment targets in ...
Regeneron’s shares have lost 10.2% in the year so far compared with the industry ’s decline of 10.6%. Currently, there are no FDA-approved treatments for the severe illness caused by SARS-CoV-2.